Biologically Active Substance

Novavax’s COVID-19 jab looks to be on track for approval

3 hours ago talkbio0Tagged Approved, COVID19 (disease), Novavax, Novavax 's, United States Food and Drug Administration, Vaccines

Vaccines, COVID19 (disease), United States Food and Drug Administration, Approved, Novavax, Novavax ‘s, Novavax

Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity

1 day ago talkbio0Tagged Biological Factors, Boost, Capacity, CDMO, Fujifilm, Manufacture, Regeneron, United States

Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

2 days ago talkbio0Tagged Approved, competition, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Novo, Obesity, Oral cavity, Pressure- physical agent, semaglutide, United States Food and Drug Administration

Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration

Trump pledges his support for a change to the IRA long sought by drugmakers

1 week ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

1 week ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

1 week ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

1 week ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization